MN HF289

Commissioner must compile by February 1 of each year (starting 2020) a list of essential diabetes drugs sold in Minnesota, including all forms of insulin, oral medications, and non-insulin injectables, along with their wholesale acquisition costs.

Manufacturers must submit annual reports by April 1 detailing production costs (excluding R&D), patient assistance program data, coupon and co-payment assistance costs, and rebates provided to pharmacy benefit managers for drugs on the list.

Manufacturers must also report by April 1 for drugs with price increases equal to or exceeding inflation rates, explaining factors contributing to increases with specific percentages and analysis.

Pharmacy benefit managers, health plan companies, and pharmacies must submit annual reports by May 1 detailing rebates received, retained rebates, fees, and cost-sharing information for listed diabetes drugs.

Commissioner must submit a public report to legislature by June 1 each year analyzing price information, reasons for increases, the effect of rebates on prices, and overall spending impact, with optional recommendations to lower drug costs.